| Gene symbol | MAGEA1 | Synonyms | CT1.1, MAGE1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | MAGE family member A1 | ||||
| GTO ID | GTC3082 |
| Trial ID | NCT05430555 |
| Disease | Advanced Solid Tumor |
| Altered gene | MAGE-A1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TK-8001 |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 (MAGE-A1-Directed TCR-Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are Not Eligible for Them or Are in a Non- Curable State and Have Received a Minimum of Two Lines of Systemic Therapy |
| Year | 2022 |
| Country | Belgium|Germany|Spain|United Kingdom |
| Company sponsor | T-knife GmbH |
| Other ID(s) | TK-8001-01|2021-004158-49 |
| Cohort 1 | |||||||||
|
|||||||||